Validity and Utility of a Hierarchical Composite Endpoint for Clinical Trials of Kidney Disease Progression: A Review

1Late Stage Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland

2Late Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

3Pharmaceuticals, Research and Development, Bayer AG, Berlin, Germany

4Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

5Pharmaceuticals, Research and Development, Bayer AG, Wuppertal, Germany

6The George Institute for Global Health, Sydney, New South Wales, Australia

Correspondence: Hiddo L. Heerspink, Department of Clinical Pharmacy and Pharmacology, University of Groningen, Hanzeplein 1, PO Box 30 001 Groningen, The Netherlands. Email: [email protected]

Comments (0)

No login
gif